Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia

Authors: Williams, R.1; Kopala, L.1; Malla, A.2; Smith, G.1; Love, L.3; Balshaw, R.3

Source: Acta Psychiatrica Scandinavica, Volume 113, Supplement 430, May 2006 , pp. 12-21(10)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

OR

Price: $48.00 plus tax (Refund Policy)

Abstract:

Williams R, Kopala L, Malla A, Smith G, Love L, Balshaw R. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.

Acta Psychiatr Scand 2006: 113 (Suppl. 430): 12–21. © 2006 Blackwell Munksgaard. Objective: 

To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment. Method: 

A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years. Results: 

Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized. Conclusion: 

There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period.

Keywords: schizophrenia; Canada; outcome assessment; hospitalization

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1600-0447.2006.00757.x

Affiliations: 1: Department of Psychiatry, University of British Columbia, Vancouver, BC 2: Department of Psychiatry, McGill University, Montreal, QC 3: Syreon Corporation, Vancouver, BC, Canada

Publication date: 2006-05-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page